-
2024-511847-24-00
4
2022-05-23
Biliary tract cancer
-
2023-508617-16-00
9
2022-05-22
Solid Tumors Dependent on KIT or PDGFRA Signaling
-
2024-515090-96-00
11
2022-05-10
Thyroid Eye Disease
-
2024-511263-28-00
6
2022-04-08
Hypercholesterolemia
-
2024-515731-29-00
4
2022-03-30
advanced stage hepatocellular carcinoma
-
2024-511187-81-00
5
2022-03-28
Colorectal Cancer (CRC)
-
2024-510869-42-00
4
2022-02-28
aortic stenosis patients with high fibrotic burden
-
2024-513916-84-00
5
2022-02-18
Severe asthma exacerbations in partial and uncontrolled preschool
asth
-
2024-511489-35-00
3
2022-01-24
Relapsed/refractory Non Hodgkin Lymphoma
-
2024-512314-17-00
5
2021-11-24
Aneurysmal Subarachnoid Hemorrhage (SAH)
-
2024-512345-16-00
4
2021-10-13
Chronic inflammatory demyelinating polyradiculoneuropathy
-
2024-512879-13-00
5
2021-09-23
Neovascular age-related macular degeneration (wet AMD)
-
2023-503388-40-00
3
2021-08-24
Non-muscle invasive bladder cancer
-
2024-511503-41-00
3
2021-08-13
Advanced or metastatic solid tumors
-
2023-508259-38-00
5
2021-04-29
Adult patients with relapsed or primary refractory DLBCL
-
2024-518182-10-00
5
2021-01-13
Acoustic schwannoma
-
2022-502480-38-00
5
2020-09-09
Non−small cell lung cancer (NSCLC)
-
2024-513948-28-00
4
2020-05-08
unresectable stage III NSCLC (Non–small-cell lung cancer)
-
2023-508293-28-00
5
2020-02-20
Dermatomyositis
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2022-502858-14-00
5
2019-09-05
Hypertrophic cardiomyopathy
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2022-502380-37-00
5
2019-08-02
Open-Angle Glaucoma
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer